On November 01, 2024, the U.S. District Court of New Jersey granted a preliminary injunction delaying the launch of LEQSELVI.
Due to the injunction, Sun Pharma has been stopped from launching LEQSELVI until a subsequent favorable court decision or until the expiry of the patent in lawsuit, whichever is earlier. “We respectfully disagree with and intend to appeal this decision immediately,” Sun Pharma said in the exchange filing.
On July 25, 2024, the U.S. Food and Drug Administration (FDA) approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.
A patent infringement action and a motion seeking a preliminary injunction were filed by lncyte Corporation and lncyte Holdings Corporation in the U.S. District Court for the District of New Jersey to prevent the launch of LEQSELVI
On August 01, 2024, Sun informed the exchange about a motion seeking a preliminary injunction filed in a US court to prevent the launch of LEQSELVI.
The Sun Group opposed that motion and action, and intend to immediately appeal this decision.
